A Three-Part Open Label Titration, Open Label Randomized Crossover, and Double Observer Single-Blind, Superiority Trial of APL-130277 compared to S.C. Apomorphine in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations

Trial Profile

A Three-Part Open Label Titration, Open Label Randomized Crossover, and Double Observer Single-Blind, Superiority Trial of APL-130277 compared to S.C. Apomorphine in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2017

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 19 May 2017 Status changed from planning to recruiting.
    • 23 Sep 2016 New trial record
    • 31 Aug 2016 According to a Sunovion Pharmaceuticals media release, this study is expected to be initiated in the fourth quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top